Johnson & Johnson (NYSE:JNJ) Trading Down 1.1% - Here's Why

Key Points

• Johnson & Johnson's stock price declined by 1.1% to $174.22 after trading as low as $174.12, with a significant decline in trading volume of roughly 23% from its average.
• Several analysts have maintained a favorable outlook on JNJ, with JPMorgan Chase & Co. raising their price objective from $185 to $200 and over half of analysts rating the stock as a Buy.
• The company announced a quarterly dividend of $1.30 per share, resulting in a dividend yield of approximately 3.0%, with a payout ratio of 55.61%.

Johnson & Johnson (NYSE:JNJ - Get Free Report)'s stock price fell 1.1% during mid-day trading on Monday . The company traded as low as $174.12 and last traded at $174.22. 6,877,786 shares changed hands during mid-day trading, a decline of 23% from the average session volume of 8,946,496 shares. The stock had previously closed at $176.19.

Wall Street Analyst Weigh In

JNJ has been the subject of a number of analyst reports. Guggenheim reaffirmed a "neutral" rating and issued a $167.00 price target (up previously from $164.00) on shares of Johnson & Johnson in a research report on Thursday, July 17th. Piper Sandler reissued an "overweight" rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. JPMorgan Chase & Co. raised their price objective on Johnson & Johnson from $185.00 to $200.00 and gave the company a "neutral" rating in a research note on Tuesday, September 16th. Royal Bank Of Canada raised their price objective on Johnson & Johnson from $181.00 to $185.00 and gave the company an "outperform" rating in a research note on Thursday, July 17th. Finally, Erste Group Bank raised Johnson & Johnson from a "hold" rating to a "buy" rating in a research note on Wednesday, July 23rd. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and ten have issued a Hold rating to the stock. According to MarketBeat.com, Johnson & Johnson currently has an average rating of "Moderate Buy" and an average target price of $178.80.

Johnson & Johnson Price Performance

The company has a market cap of $419.58 billion, a price-to-earnings ratio of 18.63, a price-to-earnings-growth ratio of 2.24 and a beta of 0.40. The company has a fifty day moving average price of $172.80 and a two-hundred day moving average price of $161.64. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The company had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. During the same quarter last year, the firm earned $2.82 EPS. Johnson & Johnson's revenue for the quarter was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, equities research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 3.0%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson's dividend payout ratio (DPR) is presently 55.61%.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares of the company's stock, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.16% of the company's stock.

Institutional Trading of Johnson & Johnson

A number of large investors have recently bought and sold shares of JNJ. Brighton Jones LLC boosted its stake in Johnson & Johnson by 13.9% in the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock worth $7,502,000 after purchasing an additional 6,332 shares in the last quarter. Two Sigma Investments LP acquired a new position in Johnson & Johnson in the fourth quarter worth $9,222,000. Castlekeep Investment Advisors LLC bought a new stake in shares of Johnson & Johnson during the fourth quarter worth $1,135,000. Vermillion Wealth Management Inc. bought a new stake in shares of Johnson & Johnson during the fourth quarter worth $133,000. Finally, Perennial Advisors LLC bought a new stake in shares of Johnson & Johnson during the fourth quarter worth $7,456,000. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.